Innovation through research and discovery
Advanced technology developed at a major university laboratory to deliver orally-dosed small molecules to the lymphatic system.
Our team of experienced professionals is advancing tomorrows cures today.
Our scientists have developed a series of novel first-in-class lymphatropic compounds which are absorbed directly into the lymphatic system following oral administration.
Targeting inhibition of specific cellular disease pathways involved in cancer, inflammation, fibrosis and host-viral interactions.
Compounds designed for simultaneous targeting of multiple compensatory signaling pathways.
Testing of pharmaceutical drugs for lymphatic uptake.
Specialists in the collection and analysis of drugs for pharmaceutical and biotech companies from plasma and lymphatic systems through contracting services.
Available partnerships to jointly develop in-house proprietary series of therapeutic compounds which have been demonstrated to be lymphatically-absorbed following oral administration.
Lympharma has unique capabilities for design of lymphatically-absorbed small molecules.
Please reach out to us with inquiries:
Nature Communications 2022 publication describing a first-in-class "Lymphatropic" multi-targeted kinase inhibitor for myelofibrosis therapy. https://lnkd.in/g9U57MpH